3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Lymphoma
54
Lymphoma, Large B-Cell, Diffuse
49
Lymphoma, Non-Hodgkin
48
Lymphoma, Mantle-Cell
37
Lymphoma, Follicular
32
Hodgkin Disease
28
Lymphoma, Large-Cell, Immunoblastic
23
Burkitt Lymphoma
22
Leukemia, Lymphocytic, Chronic, B-Cell
21
Glioblastoma
18
Precursor Cell Lymphoblastic Leukemia-Lymphoma
17
Multiple Myeloma
17
Lymphoma, B-Cell, Marginal Zone
15
Gliosarcoma
15
Brain Neoplasms
15
Central Nervous System Neoplasms
14
Neoplasms, Plasma Cell
11
Glioma
11
Astrocytoma
11
Leukemia
10
Lymphoma, B-Cell
9
Recurrence
7
Lymphoma, T-Cell
7
Waldenstrom Macroglobulinemia
5
Oligodendroglioma
5
Lymphoma, T-Cell, Peripheral
5
Lymphoma, T-Cell, Cutaneous
4
Lymphoma, Large-Cell, Anaplastic
4
Leukemia, Myeloid, Chronic-Phase
4
Leukemia, Myeloid, Acute
4
Interventions
fludarabine
4
Cyclophosphamide
4
fludarabine phosphate
3
AP 1903 reagent
3
Bendamustine Hydrochloride
2
pembrolizumab
1
isatuximab
1
ibritumomab tiuxetan
1
Rituximab
1
Radiotherapy
1
Pharmacogenomic Testing
1
Melphalan
1
Lenalidomide
1
Etoposide
1
Dexamethasone
1
Cytarabine
1
Carmustine
1
Bortezomib
1
Bone Marrow Transplantation
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Immunoproliferative Disorders
×
Carmustine
×
Clear all
NCT02366663
2018-03-12
SPINOZA
City of Hope Medical Center
Phase 3
Terminated
3 enrolled
8 charts